Topics

Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

2019-05-05 16:45:34 | BioPortfolio

Summary

This is a randomized, double-blind, placebo-controlled, clinical multicenter trial. A total of 300 patients with clinical high risk syndrome of psychosis (CHR) will be randomly allocated to SFN group (n=150) or Placebo group (n=150). The intervention duration with SFN or placebo is 52 consecutive weeks. The subsequent follow-up period is another 52 consecutive weeks. The primary endpoints are psychosis conversion rates at the end of intervention period, and one year after intervention. The secondary endpoints include the changes at different time points from baseline to study endpoints in psychotic level symptoms, predicted risk of psychosis, scores of MATRICS consensus cognitive battery, and levels of inflammation, oxidative stress, metabolism through detecting expression of related biomarkers in subjects' peripheral blood.

Description

This study is designed as a randomized, double-blind, placebo-controlled, clinical multicenter trial. The main objective of the study is to evaluate the efficacy of SFN versus placebo for decreasing risk of psychosis in patients with CHR.

A total of 300 patients with CHR will be recruited at Shanghai Mental Health Center, Shanghai Xuhui District Mental Health Center, Shanghai Pudong Nanhui Mental Health Center, Suzhou GuangJi Hospital, The Second Hospital of Xiangya in Changsha, and Guangzhou Huiai Hospital according to the inclusion and exclusion criteria. Informed consent will be obtained from each participant before participation.

CHR subjects meet the Criteria of Prodromal Syndromes (COPS) for the attenuated positive symptom syndrome (APSS), Brief Intermittent Psychotic Syndrome (BIPS), or Genetic Risk and Deterioration Syndrome (GRDS) according to the Structured Interview for Prodromal Syndromes (SIPS). CHR subjects' severity of prodromal symptoms will be assessed according to the Scale of Prodromal Symptoms (SOPS) based on the SIPS interview.

Blocked randomization is conducted for each center. Statistical Analysis System (SAS) Version 9.4 software (SAS Institute, Cary, NC, USA) is applied to generate randomization sequences by a specific statistical researcher who doesn't participate in the clinical trial. Afterwards, the allocation will be sent to each research center. Patients, physicians, researchers, data analyst, and statistician will be blinded to treatment allocation until study completion. Emergency letters containing treatment assignment will also be prepared by specific statistical researcher. Unblinding are only allowed in emergency situations when the participant indeed need further management.

A total of 300 patients with CHR will be randomly allocated to SFN group (n=150) or Placebo group(n=150). The intervention duration with SFN or placebo is 52 consecutive weeks. SFN will delivered as its precursor glucoraphanin (GR) along with a conversion enzyme, myrosinase, which converts GR to SFN in the body (providing the advantage of greater stability and a longer shelf life). Dosage will be adjusted in weight categories as follows: 40-70 kg(4 tablets = 274 μmol GR/day), 70-90kg(6 tablets=411 μmol GR/day). Placebo group will be given placebo tablets, and the number of tablets is determined according to GR and weight conversion. Active tablets and placebo tablets are manufactured uniformly with same shape and color. The subsequent follow-up period after intervention is another 52 consecutive weeks.

Clinical investigators will collect basic data such as gender, age, height, weight, and medical history at baseline. Besides, for safety and study concerns, vital signs and laboratory examination results will be taken, for instance, body temperature, arterial pulse, blood pressure, heart rate, blood routine examination, blood biochemistry, and liver and kidney function tests.

There are two primary endpoints in this study. The first one is psychosis conversion rate at the end of intervention period (52 weeks). The second one is psychosis conversion rate one year after intervention (104 weeks). Conversion is operationalized as the criteria of POPS (Presence of Psychotic Symptoms in SIPS/SOPS). Subjects had to demonstrate at least one psychotic level symptom (rated a '6') on at least one of the five P(Positive) symptoms (P1, unusual thought content; P2, suspiciousness; P3, grandiosity; P4, perceptual abnormalities; and P5, disorganized communication), with either sufficient frequency and duration or at a level that was disorganizing or dangerous. Meanwhile, the Positive and Negative Syndrome Scale (PANSS) was used for rating the severity of symptoms.

The secondary endpoints include the changes at different time points from baseline to study endpoints in psychotic level symptoms, predicted risk of psychosis, scores of MATRICS consensus cognitive battery, and levels of inflammation, oxidative stress, metabolism through detecting expression of related biomarkers in subjects' peripheral blood.

Besides, adverse events, side effects, Brief Adherence Rating Scale (BARS), drugs or therapies combination, and urinary SFN concentration will be detected and recorded.

Study Design

Conditions

Clinical High Risk Syndrome of Psychosis

Intervention

Sulforaphane, Placebo

Location

Guangzhou Huiai Hospital
Guangzhou
Guangdong
China
510009

Status

Recruiting

Source

Shanghai Jiao Tong University School of Medicine

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-05-05T16:45:34-0400

Clinical Trials [4187 Associated Clinical Trials listed on BioPortfolio]

Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers

This research study involves taking an experimental anti-cancer dietary supplement called Sulforaphane (SF) or a placebo (product without any supplement content) over a period of twelve mo...

A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia

The goal of the study is to investigate whether adding different doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia. Thi...

A 12-weeks Study to Evaluate Sulforaphane in Treatment of Autism Spectrum Disorder

In this proposed study, the investigators will evaluate the the efficacy, safety and related mechanism of sulforaphane in treatment of autism spectrum disorder (ASD). The study will recrui...

Gabapentin in Patients at Clinical Risk for Psychosis

The purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia. Researchers think that treating a bra...

PRIME vs Usual Care for Clinical High Risk

The purpose of this study is to determine whether specialty care is superior to usual care in the treatment of patients at clinical high risk for psychosis.

PubMed Articles [45476 Associated PubMed Articles listed on BioPortfolio]

Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome.

In most patients, a prodromal period precedes the onset of schizophrenia. Although clinical criteria for identifying the psychosis risk syndrome (PRS) show promising predictive validity, assessment of...

A developmentally-stable pattern of premorbid schizoid-schizotypal features predicts psychotic transition from the clinical high-risk for psychosis state.

Despite the extensive research performed on prediction of psychosis from a Clinical High Risk for Psychosis state (CHR-P), the positive predictive value of the CHR-P designation remains unsatisfactory...

Anomalous self-experiences are strongly associated with negative symptoms in a clinical high-risk for psychosis sample.

Anomalous self-experiences (ASE) are considered as central features of the schizophrenia spectrum disorders and prodromal schizophrenia. We investigated total and single-item prevalence of these pheno...

Amygdalar volume and violent ideation in a sample at clinical high-risk for psychosis.

We previously demonstrated that violent ideation predicts both violent acts and eventual progression to syndromal psychosis in individuals at clinical high-risk for psychosis (CHR). We performed amygd...

Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains.

The authors sought to characterize differences in outcomes among help-seeking individuals at clinical high risk for psychosis by identifying covariant longitudinal patterns of symptoms and functioning...

Medical and Biotech [MESH] Definitions

Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.

A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.

ANGINA PECTORIS or angina-like chest pain with a normal coronary arteriogram and positive EXERCISE TEST. The cause of the syndrome is unknown. While its recognition is of clinical importance, its prognosis is excellent. (Braunwald, Heart Disease, 4th ed, p1346; Jablonski Dictionary of Syndromes & Eponymic Diseases, 2d ed). It is different from METABOLIC SYNDROME X, a syndrome characterized by INSULIN RESISTANCE and HYPERINSULINEMIA, that has increased risk for cardiovascular disease.

An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.

Congenital or postnatal overgrowth syndrome most often in height and occipitofrontal circumference with variable delayed motor and cognitive development. Other associated features include advanced bone age, seizures, NEONATAL JAUNDICE; HYPOTONIA; and SCOLIOSIS. It is also associated with increased risk of developing neoplasms in adulthood. Mutations in the NSD1 protein and its HAPLOINSUFFICIENCY are associated with the syndrome.

More From BioPortfolio on "Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)"

Quick Search

Relevant Topics

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...


Searches Linking to this Trial